Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raltegravir - Merck & Co

Drug Profile

Raltegravir - Merck & Co

Alternative Names: Isentress; ISENTRESS HD; L 900612; MK-0518; RAL

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases; The French National Agency for Research on AIDS and Viral Hepatitis; University of Alberta
  • Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 01 Oct 2021 Biomarkers information updated
  • 29 Jun 2020 Phase-II clinical trials in Primary biliary cirrhosis (Combination therapy) in Canada (PO) (NCT03954327)
  • 08 Mar 2020 Safety, efficacy and pharmacokinetics data from a phase I/II trial in HIV-1 infection presented at the 27th Conference on Retroviruses and Opportunistic Infections (CROI-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top